Abstract
The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial showed a decrease in major adverse cardiovascular events (MACE) with low-dose rivaroxaban and aspirin vs aspirin alone in patients with a history of CAD and/or PAD. The aim of this study was to examine a) the applicability of the COMPASS trial’s population and b) potential impact of this strategy on MACE and bleeding outcomes in a North American routine clinical practice context.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
